Is Bimetinib/Bemetinib available in China?

Binimetinib is a MEK inhibitor targeted drug mainly used to treat unresectable or metastatic melanoma carrying BRAF V600E or V600K mutations. When used in combination with the BRAF inhibitor encofenib, the drug can significantly delay tumor progression and is regarded as an important breakthrough in the treatment field. However, the original drug bimetinib has not yet been officially launched in mainland China, nor has it been approved by the National Medical Products Administration (NMPA). If domestic patients want to use this drug, they usually need to purchase the overseas version through legal channels such as international medical institutions or overseas pharmacies.

Although not marketed in China, bimetinib has been widely used in the treatment of melanoma and lung cancer in Europe, the United States, Japan and other countries, and is also being studied for malignant tumors with MAPK pathway abnormalities such as colorectal cancer. Its stable efficacy demonstrated in global clinical trials makes it an important candidate for multiple solid tumor treatment combinations. With the improvement of the domestic medical system and the acceleration of the introduction of targeted drugs, bimetinib is expected to officially enter the Chinese market through import registration or cooperative introduction in the future.

For domestic patients, similar drugs currently available include MEK inhibitors such as Trametinib (Trametinib), which have been approved for use in some cases of BRAF-mutated melanoma. The development concept of bimetinib is similar to these two drugs, but it is more selective in structure and has a higher affinity for MEK1/2 kinase. Therefore, it is considered to be better tolerated and has milder side effects in doctors' practice. It is worth noting that some domestic cancer centers have cooperated with overseas pharmaceutical companies to carry out relevant clinical research, which is expected to accelerate the approval process of this drug in China in the future.

In general, bimetinib is not currently sold in mainland China, nor is it included in the medical insurance reimbursement catalog. If patients need medication, they can purchase it through regular overseas channels and use the medication rationally under the guidance of oncologists.

Reference materials:https://go.drugbank.com/drugs/DB11967